Definitions

1. Treatment arms were designed based upon accepted practices of North American neurologists.
2. Treatment arms were compared within strata defined according to the Okuda stage and the CLIP-score.
3. The treatment arms were well balanced at baseline (table 1).
4. Both treatment arms were balanced on symptom subtype.
5. Patients in the treatment arms were evenly matched for gender, age, body weight, genotype, viral load and stage of liver fibrosis.

Active Treatment Arms

1. The patients in the active treatment arms of the study were maintained at their highest tolerated dose within the respective range.

Number

1. Exploratory nature of this study makes not easy to estimate precisely the number of patients entered by physicians in different treatment arms.

Randomized Trial

1. RANDOMIZED TRIAL: A study in which participants are randomly (i.e., by chance) assigned to one of two or more treatment arms of a clinical trial.

Treatment Period

1. The number of deaths during the treatment period was similar in both treatment arms.

Remaining Patients

1. All the remaining patients either reported no change or were worse with both treatment arms.

Randomised

1. We stratified participants by health visitor and randomised them in blocks of eight to treatment arms.

Placebo

1. The size of the population placed on placebo may be smaller than the number in active treatment arms.

Stratified

1. Forty-four patients randomized to placebo or active treatment arms were stratified for gender.
2. Assignment to the four treatment arms was stratified by viral genotype and baseline HCV viral titer.
3. Time to first pneumonia analyzed using the log-rank test, stratified by smoking status and was compared across treatment arms using Kaplan-Meier estimates.

Response Rates

1. The response rates between the two treatment arms were calculated and compared using the two-sample t test.

Irrespective

1. The main analysis was comparison of treatment arms, irrespective of the H pylori status of individual patients during follow up.

Patients

1. In all treatment arms, patients with viral genotype 1, regardless of viral load, had a lower response rate.
2. Studies with less than 10 patients in treatment arms were not included [ 14].
3. Patients in the control and treatment arms had similar characteristics.

Baseline Characteristics

1. RESULTS: Of 51 IBS patients randomized, baseline characteristics were comparable among the treatment arms; the majority was diarrhea-predominant.

Incidence

1. Consistent with the results from the original analysis, the incidence of any AE was similar across the treatment arms, irrespective of GOLD stage.
2. There was no difference in the incidence of vaginal bleeding between treatment arms.

Adverse Events

1. The incidences of most adverse events in both treatment arms were generally similar in Chinese patients.
2. Less than 10% of patients in the active treatment arms discontinued study participation because of adverse events.

Study

1. In our study, the incidence and severity of AEs was generally comparable across treatment arms, regardless of GOLD stage.
2. Results: For all outcomes, both groups improved significantly over the course of the study but without any difference between the 2 treatment arms.
3. Talactoferrin was shown to be very well tolerated in the study with no major differences in adverse events between the two treatment arms.

Randomized

1. The study design was a randomized, controlled trial with 2 treatment arms.
2. Subjects who met the eligibility criteria were randomized into two different treatment arms.
3. Of the 497 patients who entered the baseline period, 421 were randomized to one of the four treatment arms.

Treatment Arms

1. RESULTS: No significant difference was observed between treatment arms and placebo in the primary end point.
2. Beginning no later than the fourth day of radiotherapy, patients are randomized to one of two treatment arms.
3. The number of patients with adverse events was similar in all treatment arms.

Categories

1. Primary End Point
2. Viral Load
3. Significant Difference
4. Randomized
5. Adverse Events
6. Books about "Treatment Arms" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -